Vyant Bio, Inc. (OTCMKTS:VYNT – Get Free Report) shares shot up 7.8% on Thursday . The stock traded as high as $0.20 and last traded at $0.19. 19,100 shares traded hands during trading, a decline of 88% from the average session volume of 161,822 shares. The stock had previously closed at $0.18.
Vyant Bio Price Performance
The company’s 50-day moving average is $0.19 and its two-hundred day moving average is $0.19. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.04.
About Vyant Bio
Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).
Featured Articles
- Five stocks we like better than Vyant Bio
- 3 Monster Growth Stocks to Buy Now
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- What Are Trending Stocks? Trending Stocks Explained
- 5 Best Gold ETFs for March to Curb Recession Fears
- What is a penny stock? A comprehensive guide
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.
